

**Supplementary Table S1.** Demographic characteristics of Treasure ax-SpA study patients.

		ax-SpA	AS	PsA	EA	nr-axSpA	Peripheric SpA	Group 1	Group 2
Sex	Female	463 (37.2)	386 (35.2)	39 (60)	10 (35.7)	16 (53.3)	12 (46.2)	16 (14.4)	38 (36.5)
	Male	783 (62.8)	711 (64.8)	26 (40)	18 (64.3)	14 (46.7)	14 (53.8)	95 (85.6)	66 (63.5)
Age		44 (36–52)	44 (36–51)	45 (38–58)	50 (45–55.5)	34.5 (29–40)	41.5 (35–48)	51 (45–61)	43.5 (39–50.5)
Age at disease onset (years)		28 (21–36)	27 (21–35)	32 (23–42)	33.5 (26–43)	26.5 (21.5–33)	30.5 (25–37)	28 (21–35)	23 (18–27)
Age at diagnosis (years)		33 (25.41)	32 (25–41)	36 (27–44)	38.5 (31–49.5)	29 (25–38)	33 (29–42)	35 (27–43)	25 (20–30.5)
Disease duration (months)		107 (58–176)	112 (60–180)	97 (47–143)	131 (31.5–192)	38.5 (18–71)	83 (27–112)	217 (124–290)	217 (196.5–246)
Delay in diagnosis (months)		26 (9–81)	29 (9–84)	12 (5–61)	30.5 (8–80)	36.5 (14–55)	12 (7–37)	61 (19–134)	13 (12–49)

Group 1: Bamboo spine. Group 2: Patients with a disease duration longer than 15 years and no syndesmophytes.

**Supplementary Table S2.** Clinical and laboratory characteristics of Treasure ax-SpA study patients.

		ax-SpA	AS	PsA	EA	nr-axSpA	Peripheric SpA	Group 1	Group 2
HLA-B27	Negative	304 (40.1)	253 (37.6)	23 (62.2)	9 (64.3)	11 (55)	8 (57.1)	17 (29.8)	17 (30.4)
	Positive	454 (59.9)	420 (62.4)	14 (37.8)	5 (35.7)	9 (45)	6 (42.9)	40 (70.2)	39 (69.6)
Smoking package/year		3.5 (0–15)	4 (0–15)	2.5 (0–12)	8 (0–24)	0,125 (0–10)	0 (0–4.5)	12,25 (1–30)	3 (0–10)
BASDAI		5.9 (4.3–6.9)	5.9 (4.2–7)	5.95 (5.2–6.8)	5.75 (4.4–6.3)	5.9 (4.9–7)	5.3 (2.8–6)	5.3 (2.6–7)	5.8 (4.8–6.5)
BASFI		4.3 (3–6.1)	4.4 (3–6.1)	4.8 (4–6.25)	4 (2.3–5)	2.8 (1.6–6.5)	4 (3.7–6)	5.5 (3–7.7)	4.65 (3.7–6)
ASDAS ESR		3.17	3.17	3.49	3.62	3.095	2.35	3.04	3.17
		(2.46–3.9)	(2.485–3.91)	(3.06–3.92)	(2.82–4.71)	(2.52–3.525)	(1.8–3.43)	(2.58–4.1)	(2.04–3.77)
ASDAS CRP		3.62	3.62	3.79	3.925	2.885	3.7	3.16	3.76
		(2.84–4.19)	(2.85–4.18)	(3.325–4.055)	(2.89–4.63)	(2.59–3.53)	(2.17–5.14)	(2.64–4.09)	(3.02–4.32)
ESR		23 (11–41)	23 (11–41)	26 (16–43)	40 (31–60)	17 (8–22)	26.5 (13.5–44)	28 (11.5–55)	23.5 (11–40)
CRP		12.8	13	14	16.5	3	17.4	17.8	15
		(4.17–27.35)	(4.5–27.7)	(5.74–29.6)	(8.86–26.5)	(1.655–6.6)	(1.98–39.7)	(7.36–46)	(5–34)
Peripheral arthritis		175 (14.3)	114 (10.6)	42 (64.6)	0 (0)	4 (13.3)	15 (57.7)	10 (9.6)	19 (18.4)
Enthesitis		202 (22.3)	170 (21.5)	12 (27.3)	7 (31.8)	8 (29.6)	5 (23.8)	25 (29.1)	11 (15.9)
Uveitis		185 (14.8)	169 (15.4)	5 (7.7)	5 (17.9)	3 (10)	3 (11.5)	28 (25.2)	17 (16.3)
Hip involvement		312 (26)	271 (25.8)	26 (40)	6 (22.2)	0 (0)	9 (34.6)	58 (53.7)	35 (34)
BMI		26.73	26.74	27.47	25.225	24.88	27.555	27.78	25.95
		(23.69–30.02)	(23.73–29.91)	(23.575–31.21)	(22.99–30.68)	(23.24–26.81)	(24.61–31.63)	(25.88–31.16)	(22.98–29.21)
MTX (Ever)		340 (27.3)	279 (25.4)	40 (61.5)	5 (17.9)	2 (6.7)	14 (53.8)	37 (33.3)	42 (40.4)
SSZ (Ever)		808 (64.8)	731 (66.6)	29 (44.6)	18 (64.3)	14 (46.7)	16 (61.5)	79 (71.2)	72 (69.2)

Group 1: Bamboo spine. Group 2: Patients with a disease duration longer than 15 years and no syndesmophytes.